Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q7Z412
UPID:
PEX26_HUMAN
Alternative names:
Peroxin-26
Alternative UPACC:
Q7Z412; F6UBB5; Q7Z413; Q7Z414; Q7Z415; Q7Z416; Q96B12; Q9NWQ0; Q9NXU0
Background:
Peroxisome assembly protein 26, also known as Peroxin-26, plays a crucial role in peroxisomal biogenesis by anchoring PEX1 and PEX6 to peroxisome membranes. This action is vital for the formation of the PEX1-PEX6 AAA ATPase complex, facilitating the extraction of the PEX5 receptor from the peroxisomal membrane, a process essential for peroxisome maintenance and function.
Therapeutic significance:
Peroxisome assembly protein 26 is implicated in a spectrum of peroxisome biogenesis disorders, including Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease. These conditions underscore the protein's critical role in cellular health and highlight the potential for targeted therapeutic strategies aimed at correcting peroxisomal biogenesis defects.